Glicerinas Industriales refused a pre-announced FDA inspection; FDA calls its glycerin drugs adulterated and placed firm on Import Alert 66-79.
What happened
FDA notified GLINSA of a planned drug manufacturing inspection for May 16 to May 20, 2022. The firm refused the pre-announced inspection during a February 24, 2022 phone call and after written notice received by UPS on March 23, 2022. FDA says the firm supplies glycerin drug components to finished drug manufacturers for the U.S. market and that glycerin contaminated with diethylene glycol has caused lethal poisonings.
What FDA found
The firm refused or limited a pre-announced FDA inspection, so its drugs are adulterated under the FD&C Act.
section 501(j) of the FD&C Act, 21 U.S.C. 351(j)
What FDA wants
Respond in writing within 15 working days to CDER-OC-OMQ-Communications@fda.hhs.gov, identifying FEI 3016420687 and ATTN: Bill Fowler. You may provide additional information for FDA to consider and/or request an FDA inspection.
Who should pay attention
- finished drug manufacturers buying glycerin from this supplier
- US brands and distributors using glycerin in drug products
- importers and suppliers of pharmaceutical ingredients
This is a summary. Read the original letter on fda.gov.